5KC.F PILA PHARMA AB

Healthcare Biotechnology Frankfurt Exchange
0.1310 EUR
Close of Nov 11, 2026
0.0869 0.2120
Market cap
EUR 5.98M
P/E
-
P/B
4.15x
ROE
-116.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 5KC.F undervalued?

Graham number

The Graham number of PILA PHARMA AB cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

PILA PHARMA AB fundamental analysis

No fundamental analysis for PILA PHARMA AB yet.

PILA PHARMA AB stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About PILA PHARMA AB

Pila Pharma AB (publ) operates as a clinical stage biotech company in Sweden. The company develops XEN-D0501, a TRPV1 antagonist in Phase 2a trial for obesity, diabetes, and heart failure; Phase 1 trial for erythromelalgia, inflammation pain, and rare diseases; and preclinical trial for abdominal aorta aneurism and cardiovascular diseases. Pila Pharma AB (publ) was incorporated in 2014 and is headquartered in Malmö, Sweden.

Full company profile